Keyword Analysis & Research: adamas pharmaceuticals
Keyword Research: People who searched adamas pharmaceuticals also searched
Search Results related to adamas pharmaceuticals on Search Engine
-
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals
https://ir.supernus.com/news-releases/news-release-details/supernus-pharmaceuticals-acquire-adamas-pharmaceuticals
Oct 11, 2021 · ROCKVILLE, Md. and EMERYVILLE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), today announced a definitive agreement for Supernus to acquire Adamas through a tender offer for $8.10 per share in cash (or an aggregate of approximately $400 million), …
DA: 18 PA: 15 MOZ Rank: 27
-
Adamas Pharmaceuticals, Inc. | LinkedIn
https://www.linkedin.com/company/adamas-pharmaceuticals-inc.
Adamas Pharmaceuticals, Inc. | 18,040 followers on LinkedIn. Making everyday life significantly better for people affected by neurological diseases. | At Adamas, our mission and vision are...
DA: 13 PA: 1 MOZ Rank: 66
-
Adamas Announces FDA Approval for Second Indication for …
https://www.businesswire.com/news/home/20210201005801/en/Adamas-Announces-FDA-Approval-for-Second-Indication-for-GOCOVRI%C2%AE-as-an-Adjunctive-Treatment-to-levodopacarbidopa-in-Parkinson%E2%80%99s-Disease-Patients-Experiencing-OFF-Episodes
Feb 1, 2021 · EMERYVILLE, Calif.-- ( BUSINESS WIRE )--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people...
DA: 3 PA: 44 MOZ Rank: 21
-
Supernus Pharmaceuticals Completes Acquisition of Adamas
https://www.globenewswire.com/news-release/2021/11/24/2340624/19871/en/Supernus-Pharmaceuticals-Completes-Acquisition-of-Adamas-Pharmaceuticals.html
ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas...
DA: 74 PA: 71 MOZ Rank: 55
-
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals
https://finance.yahoo.com/news/supernus-pharmaceuticals-acquire-adamas-pharmaceuticals-103000615.html
Oct 11, 2021 · Under the terms of the agreement, Supernus will commence a tender offer to acquire all outstanding shares of Adamas Pharmaceuticals, Inc. for a purchase price of $8.10 per share in cash (or an ...
DA: 84 PA: 10 MOZ Rank: 14
-
Adamas Announces Issuance of New Patents for GOCOVRI and …
https://www.businesswire.com/news/home/20210722005295/en/Adamas-Announces-Issuance-of-New-Patents-for-GOCOVRI-and-ADS-4101
Jul 22, 2021 · EMERYVILLE, Calif.-- ( BUSINESS WIRE )--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people...
DA: 40 PA: 97 MOZ Rank: 41
-
Adamas Reports Fourth Quarter and Full Year 2020 Financial Results
https://www.businesswire.com/news/home/20210223005961/en/Adamas-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-Results
Feb 23, 2021 · EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by ...
DA: 56 PA: 59 MOZ Rank: 78
-
Adamas Pharmaceuticals Company Profile - Craft
https://craft.co/adamas-pharmaceuticals
Adamas Pharmaceuticals $74.46 m in annual revenue in FY 2020. See insights on Adamas Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.
DA: 91 PA: 75 MOZ Rank: 52
-
Actavis and Adamas Announce FDA Approval of Namzaric™, a …
https://www.prnewswire.com/news-releases/actavis-and-adamas-announce-fda-approval-of-namzaric-a-fixed-dose-combination-of-memantine-extended-release-and-donepezil-hydrochloride-300013883.html
Dec 24, 2014 · /PRNewswire/ -- Actavis plc (NYSE: ACT) and Adamas Pharmaceuticals Inc. (NASDAQ: ADMS) today announced that the U.S. Food and Drug Administration (FDA) has...
DA: 72 PA: 26 MOZ Rank: 81
-
Supernus strikes $400M+ Adamas buyout as its top drug ... - Fierce Pharma
https://www.fiercepharma.com/pharma/supernus-strikes-400m-adamas-buyout-as-its-top-drug-heads-toward-patent-cliff
Oct 11, 2021 · In a $400 million buyout, Supernus is paying $8.10 per share to buy CNS drugmaker Adamas Pharmaceuticals. With the deal, Supernus gets rights to Gocovri, the first and only FDA-approved drug to ...
DA: 55 PA: 12 MOZ Rank: 31